This information is NOT true. The primary endpoint was met in 25% of all patients who received a dose of 200mg per day, not 35%.
In addition, the graph on the left on slide 12 in the link below can be misleading if not analyzed properly. From weeks 0 to 2, it looks as though IGA3 drops from 67.9% to about 53%. A big reason for that drop is because someone assigned to that group dropped out of the trial. They didn't actually have a reduction in disease, they left the trial so were no longer assigned to IGA3, which is why you see the drop in IGA3. This happens a couple of times throughout the graph. Just look at the percentages and do the math. Very misleading graph if you don't actually assign numbers to the percentages!
I still believe this trial showed hints of efficacy and I'm excited about the 2b results, but I think it's important for everyone to look at the RAW data, and not graphical interpretations of data with such small sample sizes with no explanation as to why the difference between ITT and PP.
News 
Market Data 
Discover 
